The impact of proton pump inhibitors in liver diseases and the effects on the liver

Yuan Bin Liu,Ming Kai Chen
DOI: https://doi.org/10.1111/1751-2980.13093
2022-04-26
Journal of Digestive Diseases
Abstract:BackgroundProton pump inhibitors are widely used as a class of drugs for the treatment of gastric acid‐related disorders. Their impact in liver diseases is also increasingly being noted.AimA systematic and comprehensive overview of the impact of proton pump inhibitors in liver diseases and their effects on the liver.MethodA manual and comprehensive search of the PubMed database was conducted to obtain relevant literature.ResultProton pump inhibitors alter the composition and function of the intestinal microflora and may lead to small intestinal bacterial overgrowth and bacterial translocation, which are associated with a range of adverse effects caused by its presence in liver diseases. They may increase the risk of hepatic encephalopathy, spontaneous bacterial peritonitis, different types of infections and increase mortality in cirrhosis. Proton pump inhibitors may lead to an increased risk of hepatic carcinoma, although the mechanism is unknown, and this relationship is still controversial. Proton pump inhibitors also have an impact on the direct‐acting antiviral regimen in patients with chronic hepatitis C. They have been associated with an increased risk of liver abscesses and increased mortality. It is possible that they may lead to a range of metabolic risk events such as liver steatosis and weight gain.ConclusionProton pump inhibitors have been associated with several adverse outcomes in liver diseases, although there is still no consistency in many respects. Clinicians should be judicious in their use of them and be aware of the indications for their use in liver diseases.This article is protected by copyright. All rights reserved.
gastroenterology & hepatology
What problem does this paper attempt to address?